ReviewInfection & chemotherapy2018
Guideline for Antibiotic Use in Adults with Community-acquired Pneumonia.
Review in Infection & chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.Frontiers in pharmacology · 2022Pooled it
- Consideration of antimicrobial resistance and contextual factors in infectious disease guidelines: a systematic survey.BMJ open · 2021Pooled it
- Clinical usefulness of repeated sputum culture for the identification of pneumonia pathogens: A retrospective study.PloS one · 2026Article
- Epidemiology and Clinical Characteristics of Community-Acquired Pneumonia in Hospitalized Patients at a Single Tertiary Center in Korea.Journal of Korean medical science · 2025Article
- Comparative Safety of Empirical Antibiotic Classes in Newly Hospitalized COVID-19 Patients.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- Global variation in antibiotic prescribing guidelines and the implications for decreasing AMR in the future.Frontiers in pharmacology · 2025Review
- Advancements in alternative approaches to address antimicrobial resistance in bacterial pneumonia: a comprehensive review.Frontiers in microbiology · 2025Review
- Age-stratified selection of albumin-based inflammatory ratios: a novel strategy for optimizing risk prediction of severe pneumonia in children.Frontiers in pediatrics · 2025Article
- Impact of antibiotic changes on hospital stay and treatment duration in community-acquired pneumonia.Scientific reports · 2024Article
- Does Phage Therapy Need a Pan-Phage?Pathogens (Basel, Switzerland) · 2024Review
- Recombinase-aided amplification assay for rapid detection of imipenem-resistantFrontiers in cellular and infection microbiology · 2024Article
- Article
- IncreasedFrontiers in cellular and infection microbiology · 2024Article
- Invasive Pneumococcal Diseases in Korean Adults After the Introduction of Pneumococcal Vaccine into the National Immunization Program.Infection & chemotherapy · 2023Review
- A score to predict Pseudomonas aeruginosa infection in older patients with community-acquired pneumonia.BMC infectious diseases · 2023Article
- Trends of legionellosis reported in Jeju Province, Republic of Korea, 2015-2022.Osong public health and research perspectives · 2023Article
- No more tears from surgical site infections in interventional pain management.The Korean journal of pain · 2023Review
- Beta-Lactam Plus Macrolide for Patients Hospitalized With Community-Acquired Pneumonia: Difference Between Autumn and Spring.Journal of Korean medical science · 2022Article
- Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin.Critical care research and practice · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Community-acquired pneumonia is common and important infectious disease in adults. This work represents an update to 2009 treatment guideline for community-acquired pneumonia in Korea. The present clinical practice guideline provides revised recommendations on the appropriate diagnosis, treatment, and prevention of community-acquired pneumonia in adults aged 19 years or older, taking into account the current situation regarding community-acquired pneumonia in Korea. This guideline may help reduce the difference in the level of treatment between medical institutions and medical staff, and enable efficient treatment. It may also reduce antibiotic resistance by preventing antibiotic misuse against acute lower respiratory tract infection in Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.